ChemicalBook >> CAS DataBase List >>Lenalidomide

Lenalidomide

CAS No.
191732-72-6
Chemical Name:
Lenalidomide
Synonyms
Revlimid;3-(4-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione;Lenalidomid;CC-5013;enaL;enalidomide;LenalidoMide (CC-5013);3-(7-amino-3-oxo-1h-isoindol-2-yl)piperidine-2,6-dione;3-(4-aMino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione;3-(4-Amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-2,6-piperidinedione
CBNumber:
CB3855432
Molecular Formula:
C13H13N3O3
Molecular Weight:
259.26
MDL Number:
MFCD18064659
MOL File:
191732-72-6.mol
MSDS File:
SDS
Last updated:2024-03-28 16:55:20

Lenalidomide Properties

Melting point 265-268 °C
Boiling point 614.0±55.0 °C(Predicted)
Density 1.460±0.06 g/cm3(Predicted)
storage temp. 2-8°C
solubility Soluble in DMSO (up to 30 mg/ml)
pka 10.75±0.40(Predicted)
form solid
color White
Stability Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.
InChI InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)
InChIKey GOTYRUGSSMKFNF-UHFFFAOYSA-N
SMILES N1C(=O)CCC(N2CC3=C(C2=O)C=CC=C3N)C1=O
CAS DataBase Reference 191732-72-6(CAS DataBase Reference)
FDA UNII F0P408N6V4
NCI Dictionary of Cancer Terms CC-5013; lenalidomide; Revlimid
NCI Drug Dictionary lenalidomide
ATC code L04AX04

Pharmacokinetic data

Protein binding 22.7-29.2%
Excreted unchanged in urine 65-85%
Volume of distribution 86 Litres
Biological half-life 3.5 / >9

SAFETY

Risk and Safety Statements

Symbol(GHS)  GHS hazard pictograms
GHS08
Signal word  Warning
Hazard statements  H361d-H373
Precautionary statements  P202-P260-P280-P308+P313-P405-P501
Risk Statements  20/21/22
Safety Statements  36/37
HazardClass  IRRITANT
HS Code  29339900

Lenalidomide price More Price(61)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Sigma-Aldrich SML2283 Lenalidomide ≥98% (HPLC) 191732-72-6 100MG $33.96 2024-03-01 Buy
Sigma-Aldrich SML2283 Lenalidomide ≥98% (HPLC) 191732-72-6 250MG $128 2024-03-01 Buy
Sigma-Aldrich 901558 Lenalidomide ≥95% 191732-72-6 100MG $50.4 2023-06-20 Buy
Sigma-Aldrich 901558 Lenalidomide ≥95% 191732-72-6 1G $171 2023-06-20 Buy
Sigma-Aldrich 901558 Lenalidomide ≥95% 191732-72-6 5G $328 2023-06-20 Buy
Product number Packaging Price Buy
SML2283 100MG $33.96 Buy
SML2283 250MG $128 Buy
901558 100MG $50.4 Buy
901558 1G $171 Buy
901558 5G $328 Buy

Lenalidomide Chemical Properties,Uses,Production

Description

Lenalidomide is a kind of antitumor drugs that developed by American biological pharmaceutical companies. Its chemical structure is similar with thalidomide. It differing in the presence of an amino moiety in the 4-position and removal of one of the carbonyls of the phthaloyl ring. This derivative evolved from a structural-based effort to eliminate the adverse effects (somnolence, neuropathy, and teratogenicity) of thalidomide while maintaining or enhancing the appealing attributes. It has many functions such as anti-tumor, immune regulation and anti-angiogenesis. It can inhibit the secretion of inflammatory cytokines, and increase the secretion of peripheral blood mononuclear anti-inflammatory cytokines. Vitro tests show that lenalidomide can inhibit the hyperplasia of some cell lines such as namalwa cell. It can inhibit the growth of patients’ multiple myeloma cells and MM1S cell. In addition, lenalidomide also can inhibit the expression of oxidase-2 (COX-2), but it has no effect on COX-1. Two multicenter randomized double-blind placebo-controlled clinical studies evaluate the safety and curative effect of lenalidomide that is used for multiple myeloma. The primary efficacy end point of the studies is time to progression (TTP). The interim analysis shows that TTP of the combination group is significantly superior to dexamethasone group. Recent clinical research results show that lenalidomide not only has curative effect on treating MDS and MM, but also on treating myeloma, leukemia, metastatic renal cell carcinoma, solid tumor, idiopathic generalized amyloidosis and systemic bone marrow fibrosis disease with marrow unripe.

Chemical Properties

Yellow Solid

Originator

Celgene (US)

History

In December 2005, the US Food and Drug Administration (FDA) approved lenalidomide to be used in the treatment of myelodysplastic syndrome (MDS).
In March 2006, the FDA approved lenalidomide that was produced by American Celgene Biological Pharmaceutical Companies to be used in the treatment of multiple myeloma (MM).
On September 23, 2011, the European Medicines Agency (EMA) released information that they have confirmed that the benefits of lenalidomide(trade name: Revlimid) to be used in the treatment of patients group that was approved outweighed the risks. Meanwhile they warned the doctor the risk of the drug to cause new cancer cases. Lenalidomide has been used with dexamethasone to treat adult patients with multiple myeloma that has received at least one treatment. Three new studies show that the incidence of new cancer will be increased in the patients with newly diagnosed multiple myeloma treated by lenalidomide and other combined treatment increased incidence of cancer.

Uses

Lenalidomide is a thalidomide analog known to have immunomodulatory properties. Lenalidomide inhibits TNF-alpha production, stimulates T cells, reduces serum levels of the cytokines vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), and inhibits angiogenesis. This agent also promotes G1 cell cycle arrest and apoptosis of malignant cells. It is used in the therapy of multiple myeloma.

Uses

Lenalidomide (Revlimid, CC-5013) is a TNF-α secretion inhibitor with IC50 of 13 nM.

Definition

ChEBI: Lenalidomide is a dicarboximide that consists of 1-oxoisoindoline bearing an amino substituent at position 4 and a 2,6-dioxopiperidin-3-yl group at position 2. Inhibits the secretion of TNF-alpha. It has a role as an angiogenesis inhibitor, an antineoplastic agent and an immunomodulator. It is a member of isoindoles, a dicarboximide, a member of piperidones and an aromatic amine.

brand name

Revlimid(Celgene).

benefits

Lenalidomide is used to treat various types of cancers. It works by slowing or stopping the growth of cancer cells. It is also used to treat anemia in patients with certain blood/bone marrow disorders (myelodysplastic syndromes-MDS). Lenalidomide may lessen the need for blood transfusions.

Biochem/physiol Actions

Lenalidomide, a derivative of thalidomide, is an immunomodulatory agent that is approved drug for treatment of multiple myeloma. Apparently Lenalidomide is a ligand of ubiquitin E3 ligase cereblon that induces the enzyme to degrade the Ikaros transcription factors IKAROS family zinc finger 1 (IKZF1) and IKZF3. Lenalidomide possess pleiotropic antitumor effects. It is used in the treatment of 5q-deletion associated myelodysplastic syndrome (del(5q)-MDS).

Mechanism of action

Lenalidomide acts by a novel drug mechanism—modulation of the substrate specificity of the CRL4CRBN E3 ubiquitin ligase. In multiple myeloma, lenalidomide induces the ubiquitination of IKZF1 and IKZF3 by CRL4CRBN. Subsequent proteasomal degradation of these transcription factors kills multiple myeloma cells.

target

TNF-α

Drug interactions

Potentially hazardous interactions with other drugs
Antibacterials: concentration possibly increased by clarithromycin.
Antifungals: concentration possibly increased by itraconazole and ketoconazole.
Calcium channel blockers: concentration possibly increased by verapamil.
Cardiac glycosides: possibly increases concentration of digoxin.
Ciclosporin: concentration possibly increased by ciclosporin.

storage

Store at -20°C

Clinical claims and research

Lenalidomide is a new derivative of thalidomide. But its teratogenic toxicity has not found. Its effectiveness is 100 times stronger than thalidomide. According to the result of three clinical trials, lenalidomide is the most effective drug in the treatment of multiple myeloma. More than half of patients can prolong survival time to more than 3 years after taking the drug. In addition, it is also the only effective drugs to treat myelodysplastic syndrome (MDS). Clinical results find that 64% of the patients with MDS need not use blood transfusion after treated by lenalidomide.

References

1) Ito et al. (2010), Identification of a primary target of thalidomide teratogenicity; Science, 327 1345
2) Gandhi et al. (2014), Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T-cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN); Br.J. Haematol., 164 811
3) Kronke et al. (2014), Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells; Science, 343 301
4) Lu et al. (2014), The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins; Science., 343 305

827026-45-9
191732-72-6
Synthesis of Lenalidomide from 3-(4-Nitro-1-oxo-1,3-dihydroisoindol-2-yl)piperidine-2,6-dione

Lenalidomide Preparation Products And Raw materials

Global( 673)Suppliers
Supplier Tel Email Country ProdList Advantage
AFINE CHEMICALS LIMITED
0571-85134551 info@afinechem.com CHINA 15377 58
Beijing Mesochem Technology Co.,Ltd
+8613651027935 rachel@mesochem.com China 191 58
Hefei TianRui Pharmaceutical Chemical Co., Ltd.
+86-0551-68665055 +86-+86-18616906106 sales@trywchem.com China 129 58
Huanfu Industrial Co.,(Shanghai)Ltd.
+86-18001856580 +86-18001856580 2415195517@qq.com China 43 58
SHANDONG BOYUAN PHARMACEUTICAL CO., LTD.
+86-0531-69954981 +8615666777973 dwyane.wang@boyuanpharm.com China 211 58
Hebei Yanxi Chemical Co., Ltd.
+8617531190177 peter@yan-xi.com China 5988 58
Henan Tengmao Chemical Technology Co. LTD
+8615238638457 salesvip2@hntmhg.com China 415 58
Henan Bao Enluo International TradeCo.,LTD
+86-17331933971 +86-17331933971 deasea125996@gmail.com China 2504 58
Zibo Hangyu Biotechnology Development Co., Ltd
+86-0533-2185556 +8617865335152 Mandy@hangyubiotech.com China 11001 58
Frapp's ChemicalNFTZ Co., Ltd.
+86 (576) 8169-6106 sales@frappschem.com China 885 50

Related articles

View Lastest Price from Lenalidomide manufacturers

Image Update time Product Price Min. Order Purity Supply Ability Manufacturer
	Lenalidomide pictures 2024-03-28 Lenalidomide
191732-72-6
US $8.00-1.00 / KG 1KG 99% g-kg-tons, free sample is available Henan Fengda Chemical Co., Ltd
Lenalidomide pictures 2024-03-26 Lenalidomide
191732-72-6
US $0.00 / Kg/Bag 2Kg/Bag 98% up, USP / BP 20tons Sinoway Industrial co., ltd.
Lenalidomide pictures 2024-03-16 Lenalidomide
191732-72-6
US $0.00 / KG 100g 98%+ 100kg WUHAN CIRCLE POWDER TECHNOLOGY CO.,LTD
  • 	Lenalidomide pictures
  • Lenalidomide
    191732-72-6
  • US $8.00-1.00 / KG
  • 99%
  • Henan Fengda Chemical Co., Ltd
  • Lenalidomide pictures
  • Lenalidomide
    191732-72-6
  • US $0.00 / Kg/Bag
  • 98% up, USP / BP
  • Sinoway Industrial co., ltd.
  • Lenalidomide pictures
  • Lenalidomide
    191732-72-6
  • US $0.00 / KG
  • 98%+
  • WUHAN CIRCLE POWDER TECHNOLOGY CO.,LTD

Lenalidomide Spectrum

3-(4-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione,Lenalidomide LenalidoMide(CC-5013,RevliMid) Lenalidomide ,98% (3S)-3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione (3R)-3-(4-aMino-1-oxo-2,3-dihydro-1H-isoindol-2-yl)piperidine-2,6-dione LenalidoMide (RevliMid) LenalidoMide-d5 3-(4-AMino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione (3S)-3-(4-amino-1-keto-isoindolin-2-yl)piperidine-2,6-quinone (3S)-3-(4-amino-1-oxo-2-isoindolinyl)piperidine-2,6-dione (3S)-3-(4-amino-1-oxo-isoindolin-2-yl)piperidine-2,6-dione (3S)-3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione lenalidomide LenalidomideLenalidomide 1-Oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline Revlimi Lenalidomide(other anti-cancers) idomide CC-5013;CC5013;CC 5013 To the amine Lenalidomide (This product is only available in Japan.) 3-(4-Amino-1-oxo-2-isoindolinyl)piperidine-2,6-dione 3-(4-amino-1-oxo-2,3-dihydro-1H-isoindol-2-yl)piperidine-2,6-dione Leflunomidum Lenalidomide USP/EP/BP Lenadoamide 99% purity Lenalidomide Lenalidomide (Revlimid, CC5013) LenalidomideQ: What is Lenalidomide Q: What is the CAS Number of Lenalidomide Q: What is the storage condition of Lenalidomide Q: What are the applications of Lenalidomide Revlimid 3-(4-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione 3-(4-aMino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione LenalidoMide (CC-5013) 3-(7-amino-3-oxo-1h-isoindol-2-yl)piperidine-2,6-dione 3-(4-Amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-2,6-piperidinedione CC-5013 enalidomide Lenalidomid enaL 2-Propenoicacid,2-(6-hydroxyethoxy)ethylester Lenalidomide API (3S)-3-(4-AMIN0-1-0X0-1, 3- DIHYDR0-2H-IS0IND0L-2- YDPIPERIDINE-2, 6-DIONE Lenalidomide (Form A) Lenalidomide 3-(4-Amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-2,6- piperidinedione 191732-72-6 25926 Amines Heterocycles Intermediates & Fine Chemicals Pharmaceuticals Inhibitor CC-5013 Inhibitors Molecular Targeted Antineoplastic pharmaceutical intermediate API 191732-72-6